WAVE Life SciencesFRA:1U5 -4.59%59 Median PS Value is €8.05 as of Jul. 12, 2026, which is 100% below its 10-year median of 0.57. GuruFocus rates FRA:1U5 with a GF Score™ of 59/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 278 Biotechnology companies, WAVE Life Sciences ranks worse than 50.36% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for WAVE Life Sciences's Median PS Value or its related term are showing as below:
FRA:1U5'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38 Med: 0.57 Max: 2.69
Current: 0.65
During the past 13 years, the highest Price to Median PS Value of WAVE Life Sciences was 2.69. The lowest was 0.38. And the median was 0.57.
FRA:1U5's Price-to-Median-PS-Value is ranked worse than 50.36% of 278
companies
in the Biotechnology industry
Industry Median: 0.645
vs FRA:1U5: 0.65
WAVE Life Sciences (FRA:1U5) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
WAVE Life Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
5.20
/
8.05
=
0.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences Median PS Value Related Terms
WAVE Life Sciences Median PS Value Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1U5 vs CGEM, LXRX, XNCR: Median PS Value Comparison
For the Biotechnology subindustry, WAVE Life Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 24.247.
WAVE Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.332.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (FRA:1U5) has a Median PS Value of €8.05 as of Jul. 12, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on WAVE Life Sciences and its competitors. This is 1312% above median its historical median of 0.57. Over the past decade, WAVE Life Sciences' Median PS Value has ranged from 0.38 to 2.69. According to the industry distribution chart, WAVE Life Sciences ranks #140 out of 278 companies in the Biotechnology industry, placing it in the top 50.4%.
Is WAVE Life Sciences' Median PS Value too high?
WAVE Life Sciences' current Median PS Value of €8.05 is 1312% above median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 2.69. Based on the distribution chart, WAVE Life Sciences ranks #140 out of 278 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' Median PS Value compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #140 out of 278 companies for Median PS Value. This places WAVE Life Sciences in the lower half of its industry. The industry median Median PS Value is 0.65. Historically, WAVE Life Sciences' own Median PS Value has ranged from 0.38 to 2.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current Median PS Value is €8.05, which is 1312% above median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €5.20 — trading 42.9% above its estimated fair value. The current Median PS Value is €8.05, which is 1312% above median its 10-year median of 0.57. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current Median PS Value is €8.05 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of €5.20 is trading 42.9% above its estimated GF Value™ of €3.64.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:1U5:
Median PS Value: €8.05 (1312% above median its 10-year median of 0.57)
GF Value™: €3.64 vs. price of €5.20 (42.9% above fair value)
No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for FRA:1U5
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1U5 has been successfully added to your 
